Benitec Biopharma Limited
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia. Show More...
-
Website http://www.benitec.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 15.36 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-06 2011-06 2012-06 2013-06 2014-06 2015-06 2016-06 2017-06 2018-06 2019-06 TTM Earnings Per Share AUD -0.08 -0.1 -0.1 -0.17 -0.03 -0.06 0.02 -0.04 Dividends AUD Payout Ratio % * Shares Mil 90.0 116.0 116.0 142.0 175.0 210.0 257.0 275.0 Book Value Per Share * USD 0.2 0.13 0.09 0.04 0.08 0.04 Free Cash Flow Per Share * USD -0.05 -0.13 -0.03 -0.03 0.010 Return on Assets % -20.41 -38.35 -45.1 -109.13 -26.74 -52.9 16.79 -36.15 Financial Leverage (Average) 1.03 1.07 1.07 1.06 1.05 1.14 1.16 1.07 Return on Equity % -20.99 -40.09 -48.2 -116.02 -28.21 -57.84 19.31 -38.83 Return on Invested Capital % -20.99 -40.09 -48.2 -116.02 -28.21 -57.84 18.51 -38.37 Interest Coverage Current Ratio 36.07 15.26 15.26 18.73 19.7 8.2 7.1 20.3 Quick Ratio 32.96 13.34 13.42 18.56 19.45 8.0 6.92 19.46 Debt/Equity 0.02